The company has appointed Aradhana Sarin as new Chief Financial Officer.
Marc Dunoyer to retire from the Board and take up a new senior executive role with the company, it states in a press release.
Operating roles at Alexion and advisory roles at global financial institutions
The Board has appointed Aradhana Sarin as an Executive Director and Chief Financial Officer, conditional upon closing of AstraZeneca’s acquisition of Alexion Pharmaceuticals, Inc. and effective on the later of 1 August 2021 or the date of Closing, which is expected to take place in the third quarter of 2021, subject to receipt of certain regulatory approvals.
Sarin is currently Executive Vice-President, Chief Financial Officer of Alexion. She joined Alexion in November 2017, serving as Chief Business and Strategy Officer prior to becoming Chief Financial Officer. She has more than 20 years of professional experience spanning operating roles at Alexion and advisory roles at global financial institutions, gaining extensive knowledge of global healthcare systems, capital markets and strategic transactions.
Sarin will relocate from the US and be based in the UK. She will report to AstraZeneca’s Chief Executive Officer, Pascal Soriot.
A medical doctor in India
Prior to joining Alexion, Dr. Sarin was Managing Director, Healthcare Corporate & Investment Banking, Citi Global Banking in New York where she advised clients in the life sciences and biopharmaceutical sectors. Before that, she was Managing Director, Healthcare Investment Banking, UBS, in New York and San Francisco and worked at JP Morgan in New York in the M&A Advisory and Healthcare groups.
Prior to her banking career, Dr. Sarin trained as a medical doctor in India and spent two years practising in both India and Africa. She completed her medical training (M.B.B.S.) at the University of Delhi in India and received her MBA from Stanford Business School in the US.
From 2018 to 2020, Dr. Sarin was a member of the board of OraSure Technologies, Inc., serving as Chairman of the Audit Committee and a member of the Nominating and Corporate Governance Committee.
Conditional upon Closing and effective the same date as his retirement from AstraZeneca’s Board, Mr. Dunoyer will become Chief Executive Officer, Alexion and Chief Strategy Officer, AstraZeneca. He will continue to report to Mr. Soriot and will remain a member of AstraZeneca’s Senior Executive Team.
“On behalf of the Board, I’d like to thank Marc for his significant contribution to AstraZeneca’s success since he joined us in 2013. We’re pleased he’s staying with the Company, taking on a new senior executive role and look forward to continuing to work with him,” says Leif Johansson, Chairman of AstraZeneca.
Photo of Aradhana Sarin: Alexion